Together we can create something truly inspirational.
It is such a privilege to support the next generation of life science technology. Our investments focus on meaningful causes that enhance the healthcare journey, save costs or save lives. Having more insight into medtech, biotech and pharmaceutical developments over the past few years has been an eye opener for me and revealed how truly talented our UK scientists and business leaders are. We see hundreds of outstanding innovations each year and carefully select those to join our portfolio of investments.
Patricia Reynolds, CEO

Patricia is the founder and Chief Executive Officer of Norcliffe Capital. Having worked in finance for over 26 years, Patricia has a wealth of professional experience in advisory, finance and private equity.

Since 2013, Patricia focused exclusively on pre-investment due diligence, capital fundraising under the EIS and SEIS and post-investment business management. Her representative transactions cover a range of industries including life sciences, healthcare, technology and IoT.

Prior to this, Patricia spent 15 years at RBS providing strategic financial advice for the corporate and commercial banking sectors.

Patricia holds a number of professional financial qualifications and is a regular speaker at industry events.

Pitch Deck Services
Development of Financial Models
Corporate Financial Advisory
Deal Structuring
I was on my fourth retirement when Patricia asked me to advise Norcliffe Capital and while I enjoy fishing and gardening making a difference in MedTech has always been my passion so, the decision was easy! It has been an exciting experience talking to young scientists and entrepreneurs across the UK about their ideas to improve people’s lives and create great companies. We have developed a rigorous selection process which means we only support around 4 high quality companies a year.
Professor David Onions, CSA

David Onions, PhD FMedSCi DVMS(hon) FRSA FRSE, is an investor in biomedical companies and former Chief Medical Officer of Invitrogen/Life Technologies (now Thermo Fisher). He founded 2 biotechnology companies (Q-One Biotech and BioOutsource) which, in total, exited for ˜$100M and he was involved in the buy-out of BioReliance which was sold for $350M to Sigma-Aldrich (now Merck KGaA).

He was formerly a member of the board of BioReliance, VP of its commercial operations and the Chief Scientific Officer of the company. Prior to that he was a founder and President of Q-One Biotech Inc., a company involved in the GMP production and safety evaluation of biotechnology products. The company was awarded the Scottish Council for Development & Industry Award 2002 and the Biotech Scotland Award 2002. In 2003 the company was acquired by Invitrogen (now Thermo-Fisher) where David Onions became the Chief Medical Officer, overseeing the company’s developments of clinically based molecular programs.

Read More

External Advisory Group

We have built an organisation that attracts people of only the highest calibre, with great experience and expertise.